EP
AMPH icon

Essential Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Essential Partners’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82K Sell
90
-31
-26% -$625 ﹤0.01% 2010
2026
Q1 		$2.37K Sell
121
-79
-40% -$1.93K ﹤0.01% 1936
2025
Q4 		$5.36K Sell
200
-50
-20% -$1.29K ﹤0.01% 1399
2025
Q3 		$6.66K Buy
250
+94
+60% +$2.43K ﹤0.01% 1311
2025
Q2 		$3.58K Buy
+156
New +$3.87K ﹤0.01% 1146

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's AMPH Position: Q2 2026 in Review

Essential Partners reduced its Amphastar Pharmaceuticals (AMPH) stake by 26% in Q2 2026, selling an estimated $625 and leaving 90 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Essential Partners first reported a position in AMPH in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.66K in Q3 2025. 210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Essential Partners held 90 shares of Amphastar Pharmaceuticals worth $1.82K as of Q2 2026.
  • Essential Partners sold 31 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $625.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2010 holding.
  • Essential Partners first reported a position in Amphastar Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Amphastar Pharmaceuticals position peaked at $6.66K in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.